Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Phase II Trial Evaluating the Endocrine Activity and Efficacy of Neoadjuvant Degarelix Versus Triptorelin in Premenopausal Patients Receiving Letrozole for Primary Endocrine Responsive Breast Cancer

Next Previous
X
Search
Trial Profile

A Randomized Phase II Trial Evaluating the Endocrine Activity and Efficacy of Neoadjuvant Degarelix Versus Triptorelin in Premenopausal Patients Receiving Letrozole for Primary Endocrine Responsive Breast Cancer

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 19 Aug 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Degarelix (Primary) ; Letrozole; Triptorelin
  • Indications Early breast cancer
  • Focus Therapeutic Use
  • Acronyms TREND

    • Most Recent Events

    • 28 May 2019 Status changed from active, no longer recruiting to completed.
    • 27 Dec 2018 Results evaluating endocrine activity in terms of ovarian function suppression of degarelix in premenopausal patients receiving letrozole as neoadjuvant endocrine therapy for breast cancer. published in the Journal of Clinical Oncology
    • 12 Dec 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Mar 2018.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top